Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $1.41, 36% below $2.19, its close on the day of its Oct 1 underwritten offering. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$55.6MCash on Hand
9.7mo Cash Runway
Follow PYXS by emailGet an email when PYXS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PYXS, unsubscribe in one click. Privacy
📣 What PYXS Says Is Next
second half of 2027 · “Durability data are expected in the second half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
second half of 2027 · “Additional data from the Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first-line (1L) R/M HNSCC, including initial durability data to inform selection of the recommended Phase 3 dose, are expected in the second half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
first half of 2027 · “Updated overall survival data from the ongoing MICVO monotherapy study are expected in the first half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Shareholder vote Stockholders approved increasing authorized common stock from 190,000,000 to 380,000,000 shares at a November 13, 2026 special meeting, with 78,081,809 votes for and 6,706,849 against. The charter amendment took effect on filing. Form 8-K · SEC filing
Nov 5, 2026 ·
Earnings Pyxis Oncology reported Q3 2026 results of $57.0M cash and short-term investments and R&D expense of $16.6M, and said cash plus October offering proceeds funds operations into the first half of 2028. Phase 3 trial start is planned for mid-2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 21, 2026 ·
Shareholder vote Pyxis Oncology will hold a virtual special meeting on November 13, 2026 where stockholders vote on increasing authorized common stock from 190,000,000 to 380,000,000 shares, plus an adjournment proposal. The board recommends FOR both. Form DEF 14A · SEC filing
Oct 1, 2026 ·
Financing Pyxis Oncology is offering 36,047,919 shares of common stock at $2.90 per share, plus pre-funded warrants for 1,883,121 shares and common warrants for 49,310,352 shares at a $3.50 exercise price. The common warrants cannot be exercised until stockholders approve an increase in authorized shares. Form 424B5 · SEC filing
Oct 1, 2026 ·
Financing Pyxis Oncology closed an underwritten offering on October 1, 2026, selling 36,047,919 shares and 1,883,121 pre-funded warrants, each paired with common warrants for 1.3 shares, at a combined $2.90 per share. Net proceeds were about $102.8 million. Form 8-K · SEC filing
Sep 29, 2026 ·
Financing Pyxis Oncology terminated its at-the-market stock sale program with Leerink Partners, reducing the amount available under the $150,000,000 prospectus supplement to $0. No shares had been sold under the program. Form 424B5 · SEC filing
Sep 29, 2026 ·
Financing Pyxis Oncology proposes a public offering of common stock, pre-funded warrants and common warrants, with the warrants exercisable only after stockholders approve an increase in authorized shares. Offering amounts and prices are left blank in this preliminary prospectus supplement. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 1 · Recruiting · A Study of PYX-201 in Advanced Solid Tumors Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PYXS's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PYXS holds $55.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $17.3M/quarter from operations,
an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:60 · High
Cash runway 10 months +30
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Nov 2025) +10
Company says cash lasts into the first half of 2028 -5We expect that our existing cash, cash equivalents and marketable debt securities, together with the net upfront proceeds from the public offering, will be sufficient to fund our operating expenses and capital expenditure requirements into the first half of 2028.10-Q, Nov 2026
Share count +92% in a year +20
Raised after last reported balance sheet (Oct 2026) -10
Share count 119,607,855 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PYXS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PYXS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.